- Report
- February 2024
- 110 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Report
- January 2021
- 600 Pages
United States
From €2690EUR$2,800USD£2,300GBP
- Report
- November 2020
- 124 Pages
Global
From €1153EUR$1,200USD£986GBP
- Report
- March 2023
- 111 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- March 2021
- 94 Pages
Global
€21139EUR$22,000USD£18,072GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Report
- December 2021
- 120 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- July 2023
- 123 Pages
China
From €1730EUR$1,800USD£1,479GBP
- Report
- April 2023
- 129 Pages
Global
€4804EUR$5,000USD£4,107GBP
- Report
- August 2023
- 91 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- July 2023
- 244 Pages
China
From €3843EUR$4,000USD£3,286GBP
Leuprolide is a synthetic hormone used to treat prostate cancer. It is a gonadotropin-releasing hormone (GnRH) agonist, meaning it works by blocking the production of testosterone, which can slow the growth of prostate cancer cells. Leuprolide is typically administered via injection, and is available in both short-acting and long-acting formulations. It is often used in combination with other treatments, such as radiation therapy or chemotherapy.
Leuprolide is a widely used treatment for prostate cancer, and is often prescribed as a first-line therapy. It is generally well-tolerated, with few side effects. Common side effects include hot flashes, fatigue, and nausea.
The leuprolide market is highly competitive, with several major players. These include AbbVie, Astellas Pharma, Endo Pharmaceuticals, and Takeda Pharmaceuticals. Other companies, such as Mylan and Teva Pharmaceuticals, also offer leuprolide products. Show Less Read more
